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Background.  —  Large  interindividual  variability  exists  in  clopidogrel  response.  Clopidogrel  low
response correlates  with  poor  prognosis  after  percutaneous  coronary  intervention.  Some  authors
also suggest  intraindividual  variability  over  time.
Aim. —  To  assess  the  impact  of  initial  clinical  presentation  on  clopidogrel  low  response.
Methods.  —  In  this  prospective  study,  clopidogrel  response  was  assessed  in  100  patients.  Fifty
patients  presenting  with  acute  coronary  syndromes  (ACS  group)  were  compared  with  50  patientsAcute  coronary
syndromes
with stable  coronary  artery  disease  matched  1:1  for  age,  sex,  body  mass  index  and  diabetes
(stable group).  All  patients  were  tested  18—24  h  after  a  600  mg  loading  dose  of  clopidogrel
using the  VerifyNow-P2Y12  test  (results  expressed  as  platelet  reaction  units  [PRUs]).  Patients
under chronic  clopidogrel  therapy  or  treated  with  glycoprotein  IIb/IIIa  inhibitors,  bivalirudin  or
thrombolytics  were  excluded.
Abbreviations: ACS, acute coronary syndromes; ADP, adenosine diphosphate; BMI, body mass index; PCI, percutaneous coronary inter-
vention; PRU, platelet reaction unit.
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Results.  —  Mean  age  was  61  ±  12  years  in  each  group;  28%  of  patients  in  each  group  were  dia-
betic; mean  body  mass  index  was  27.6  ±  5.6  kg/m2 in  the  ACS  group  and  27.9  ±  5.9  kg/m2 in
the stable  group  (p  =  0.80).  Mean  PRU  values  were  197  ±  81  in  the  ACS  group  and  159  ±  94  in
the stable  group  (p  =  0.03).  By  multivariable  analysis,  the  ACS  group  was  signiﬁcantly  associated
with a  higher  PRU  value  (p  =  0.02).  There  were  signiﬁcantly  more  clopidogrel  low  responders
(PRU value  >  230)  in  the  ACS  group  (38%  vs.  18%;  p  =  0.04).
Conclusion.  —  Our  study  conﬁrms  that  initial  clinical  presentation,  especially  ACS,  is  a  strong
predictor of  clopidogrel  low  response;  this  suggests  that  the  evolution  of  coronary  artery  disease
for one  patient  inﬂuences  the  clopidogrel  response  over  time.  These  results  are  in  accordance
with recent  trials  showing  a  beneﬁt  for  more  aggressive  antiplatelet  therapy  in  ACS  patients.













Contexte.  —  Une  mauvaise  réponse  biologique  au  clopidogrel  est  associée  à  un  pronostic  défa-
vorable des  patients  après  angioplastie  coronaire  percutanée  (ACP).  Il  est  clairement  démontré
qu’il existe  une  large  variabilité  interindividuelle  dans  la  réponse  au  clopidogrel.  Certains
auteurs suggèrent  également  la  présence  d’une  variabilité  intraindividuelle  au  cours  du  temps.
Objectif.  —  Nous  avons  analysé  l’impact  de  la  présentation  clinique  initiale  sur  la  réponse  au
clopidogrel.
Méthodes. —  Dans  cette  étude  prospective,  la  réponse  biologique  au  clopidogrel  a  été  analysée
chez 100  patients.  Au  total,  50  patients  présentant  initialement  un  syndrome  coronaire  aigu
(groupe SCA)  ont  été  appariés  1:1  à  50  patients  présentant  un  angor  stable  (groupe  stable)
sur l’âge,  le  sexe,  l’indice  de  masse  corporelle  et  le  diabète.  Tous  les  patients  ont  été  testés
par le  test  du  VerifyNow-P2Y12  (résultats  exprimés  en  platelet  reaction  unit  [PRU])  entre  18
et 24  heures  après  une  dose  de  charge  de  600  mg  de  clopidogrel.  Les  patients  traités  au  long
cours par  clopidogrel,  ceux  ayant  rec¸u  un  ﬁbrinolytique,  de  la  bivalirudine  ou  un  inhibiteur  du
récepteur  Gp  IIb/IIIa  ont  été  systématiquement  exclus  de  cette  étude.
Résultats.  —  L’âge  moyen  était  de  61  ±  12  ans  dans  chaque  groupe.  Au  total,  28%  des  patients
étaient diabétiques  dans  chaque  groupe  et  l’indice  de  masse  corporelle  était  de  27,6  ±  5,6  et
27,9 ±  5,9  kg/m2 dans  le  groupe  « SCA  » et  dans  le  groupe  « stable  »,  respectivement  (p  =  ns).
Les valeurs  de  PRU  moyennes  étaient  de  197  ±  80  et  159  ±  94  dans  le  groupe  « SCA  » et  dans
le groupe  « stable  »,  respectivement  (p  =  0,033).  En  analyse  multivariée,  le  groupe  « SCA  » était
signiﬁcativement  associé  à  des  valeurs  de  PRU  plus  élevées  (p  =  0,018).  Il  y  avait  signiﬁcative-
ment plus  de  « mauvais  répondeurs  » (déﬁnis  comme  une  valeur  de  PRU  >  230)  dans  le  groupe
« SCA  » (18%  vs  38%;  p  =  0,04).
Conclusion.  — Cette  étude  conﬁrme  que  la  présentation  clinique  initiale,  notamment  le  SCA,  est
un facteur  prédictif  puissant  de  mauvaise  réponse  au  clopidogrel.  Elle  suggère  également  que
l’évolution  de  la  maladie  coronaire  pour  un  patient  donné  inﬂuence  la  réponse  au  clopidogrel
au cours  du  temps.  Ces  résultats  sont  en  accord  avec  les  récents  essais  montrant  un  bénéﬁce  à
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ackground
arge  interindividual  variability  exists  in  response  to  clopid-
grel  [1—11].  In  2002,  Jaremo  et  al.  were  the  ﬁrst  to  report
nterindividual  variability  in  clopidogrel  response  after  a
00  mg  loading  dose  and  by  using  a  ﬂow  cytometry  tech-
ique  with  adenosine  diphosphate  (ADP)  as  agonist  [8].
ince  then,  these  results  have  largely  been  conﬁrmed  by
umerous  studies  using  either  light  transmission  aggregom-
try  [5—7],  the  vasodilator-stimulated  protein  test  [1—5]
r  the  VerifyNow-P2Y12® test  [10,11].  However,  according
o  a  recent  meta-analysis,  the  rate  of  ‘‘low  responders’’
mong  patients  undergoing  percutaneous  coronary  interven-
ion  (PCI)  varies  greatly  from  10%  to  50%  (average  21%)  [12].
ndeed,  the  methodologies  of  the  different  studies  some-
imes  differ  widely:  loading  dose  of  clopidogrel,  type  of  test
[
t
ss  droits  réservés.
sed,  deﬁnition  of  low  response  used,  type  and  quantity  of
gonist  used,  timing  of  the  test  after  the  loading  dose,  etc.
Of  main  importance,  clopidogrel  low  response  has  been
hown  to  correlate  strongly  with  poor  prognosis  after  PCI.
ndeed,  many  studies  have  shown  an  increased  risk  of  death,
yocardial  infarction  and/or  major  adverse  cardiovascular
vents  [1—11].  The  meta-analysis  of  Snoep  et  al.,  which
ncluded  25  studies  and  3688  patients,  reported  a  pooled
dds  ratio  for  major  adverse  cardiovascular  events  of  8  (95%
onﬁdence  interval  3.4—19)  in  clopidogrel  low  responders
ompared  with  ‘‘good  responders’’  [12].
It  is  critical,  therefore,  to  identify  predictors  of  clopido-
rel  low  response.  Genetic  polymorphism  (CYP2C19*2,  etc.)
13—17],  diabetes  [18], obesity  [19]  and  treatment  interac-
ion  (e.g.  with  proton  pump  inhibitors)  [14,20]  have  been
hown  to  signiﬁcantly  impact  the  clopidogrel  response.  In



















































bFigure 1. Study design. ACS: acute coronary syndromes; BMI:
body mass index.
addition,  some  authors  also  suggest  intraindividual  variabil-
ity  over  time.
This  study  aims  to  assess  the  impact  of  initial  clinical
presentation  just  before  stenting  (either  acute  coronary  syn-
dromes  [ACS]  or  stable  coronary  artery  disease  [CAD])  on
clopidogrel  low  response.
Methods
Study design and population
In  this  prospective  study,  clopidogrel  response  was  assessed
in  100  patients  in  our  catheter  laboratory.  All  patients  were
included  between  November  2010  and  August  2011  and
gave  their  informed  consent  to  the  study.  Fifty  patients
presenting  with  ACS  (ACS  group)  were  compared  with  50
patients  with  stable  CAD,  matched  1:1  for  age  (±3  years),
sex,  body  mass  index  (BMI  ±  1  kg/m2)  and  diabetes  (sta-
ble  group).  All  patients  in  the  stable  group  underwent  a
coronary  angiogram  in  the  context  of  stable  angina  and/or
documented  silent  ischaemia.  All  patients  were  tested  for
platelet  reactivity  and  clopidogrel  response  18—24  hours
after  a  600  mg  loading  dose  of  clopidogrel  using  the
VerifyNow-P2Y12® test  (Accumetrics,  San  Diego,  CA,  USA).
The  study  ﬂow  chart  is  displayed  in  Fig.  1.
Power calculation
After  a  600  mg  loading  dose  of  clopidogrel,  Cuisset  et  al.
reported  a  mean  platelet  reaction  unit  (PRU)  value  of
199  ±  93  (using  the  VerifyNow-P2Y12® test)  in  patients  with
stable  CAD  [21].  Similarly,  Price  et  al.  found  a  mean  PRU
value  of  184  ±  85  in  stable  patients  [11].  By  contrast,  Patti
et  al.  reported  higher  PRU  values  (258  ±  53)  in  a  population
of  patients  of  whom  60%  had  ACS  [10].  Based  on  these  previ-
ous  results,  the  expected  mean  PRU  values  of  250  in  the  ACS
group  and  190  in  the  stable  group  and  the  expected  standard
deviation  of  90,  49  patients  were  needed  in  each  group  to
achieve  a  power  of  90%  and  a  signiﬁcance  level  ()  of  5%.
Altogether,  100  patients  were  included  in  the  present  study:






he  exclusion  criteria  were  as  followed:  patients  aged  <  18
ears;  pregnant  women;  patients  who  did  not  consent  to
he  study  or  who  lacked  the  capacity  to  consent;  patients
n  chronic  clopidogrel  treatment  (or  another  ADP  recep-
or  antagonist)  before  the  loading  dose;  patients  treated
ith  thrombolytic  therapy,  bivalirudin  and/or  glycoprotein
Ib/IIIa  inhibitors;  patients  with  a  platelet  count  <  100  Giga/L
nd/or  a  haematocrit  level  <  30%;  and  patients  in  cardio-
enic  shock.
rimary endpoint
he  aim  of  the  present  study  was  to  assess  the  impact
f  the  initial  clinical  presentation  of  patients  undergoing
CI  on  clopidogrel  response.  The  primary  endpoint  was  to
ompare  the  mean  PRU  value  (using  the  VerifyNow-P2Y12®
est)  between  the  two  groups:  the  ACS  group  and  the  stable
roup.
lopidogrel low response assessment
ll  patients  were  tested  for  platelet  reactivity  and  clo-
idogrel  response  18—24  h  after  a  600  mg  loading  dose
f  clopidogrel  using  the  VerifyNow-P2Y12® test  [22].  The
erifyNow-P2Y12® System  is  an  automated  point-of-care
urbidimetry-based  optical  detection  system  that  measures
latelet-induced  aggregation.  The  system  consists  of  an
nalyser  instrument  and  a  disposable  assay  device.  The
nstrument  controls  all  assay  sequencing,  the  temperature
nd  reagent  sample  mixing  and  performs  self-diagnostics.
he  assay  device  contains  a  lyophilized  preparation  of
uman  ﬁbrinogen-coated  beads,  platelet  activators  and
uffer.  The  patient  sample  is  whole  blood,  automatically
ispensed  from  the  blood  collection  tube  into  the  assay
evice  by  the  instrument.  The  VerifyNow-P2Y12® assay
ontains  20  mol  ADP  and  22  mol  prostaglandin  E1  to
educe  the  activation  contribution  from  ADP  binding  to
2Y1  receptors.  The  VerifyNow-P2Y12® instrument  measures
latelet-induced  aggregation  as  an  increase  in  light  trans-
ittance  and  uses  a  proprietary  algorithm  to  report  values
n  PRUs  and  percentage  of  platelet  inhibition.  A  higher  PRU
alue  reﬂects  greater  P2Y12-mediated  reactivity.  According
o  the  literature,  clopidogrel  low  responders  are  deﬁned  as
atients  with  a  PRU  value  >  230  [23].
tatistical analysis
ontinuous  variables  are  expressed  as  means  ±  standard
eviations.  Categorical  variables  are  expressed  as  absolute
umbers  and  percentages.  Baseline  characteristics  between
he  two  groups  were  compared  using  the  chi-square  test  or
isher’s  test  for  categorical  variables  and  Student’s  unpaired
 test  for  continuous  variables,  as  appropriate.  Correla-
ions  between  the  clopidogrel  response  (PRU  values  assessed
s  a  continuous  variable)  and  the  different  tested  varia-
les  were  evaluated  using  Pearson’s  correlation  test  for
ontinuous  variables  and  Student’s  t  test  for  categorical
ariables.  A  multivariable  analysis  was  then  performed  using
inear  regression  and  including  the  following  variables:  age,
ex,  ACS  group,  BMI,  diabetes,  renal  failure,  proton  pump


























































































nhibitor  use  and  all  variables  with  a  p  value  <  0.2  in  univari-
te  analysis.  To  identify  the  predictors  of  low  responders
PRU  values  assessed  as  a  categorical  variable  with  a cut-off
oint  of  230,  according  to  the  literature)  [23],  the  different
ariables  were  tested  using  the  chi-square  test.  A  multivari-
ble  analysis  was  then  performed  using  logistic  regression
nd  including  the  following  variables:  age,  sex,  ACS  group,
MI,  diabetes,  renal  failure,  proton  pump  inhibitor  use  and
ll  variables  with  a  p  value  <  0.2  in  univariate  analysis.
ll  statistical  analyses  were  performed  with  SPSS  17.0  for
indows® software  (SPSS  Inc.,  Chicago,  IL,  USA).  Statistical
igniﬁcance  was  assumed  at  a  p  value  <  0.05.
esults
opulation
aseline  clinical  characteristics  of  the  population  are  sum-
arized  in  Table  1.  The  two  groups  were  well  matched  for
ge,  sex,  diabetes  and  BMI.  The  mean  age  was  61  ±  12  years
n  each  group,  28%  of  patients  in  each  group  were  diabetic
nd  the  mean  BMI  was  27.6  ±  5.6  kg/m2 in  the  ACS  group  and
7.9  ±  5.9  kg/m2 in  the  stable  group  (p  =  0.80).  No  signiﬁcant
ifferences  were  noted  between  the  two  groups  among  the
ther  variables.  In  the  ACS  group,  26  (52%)  patients  pre-
ented  as  ST-segment  elevation  myocardial  infarction  and
4  (48%)  patients  as  non-ST-segment  elevation  myocardial
nfarction.
Baseline  biological  characteristics  are  summarized  in
able  2.  Mean  haematocrit,  platelet  count  and  creatinine
evels  were  similar  between  the  two  groups.  Mean  gly-
osylated  haemoglobin  was  6.7  ±  1.5%  in  the  ACS  group
nd  6.8  ±  1.6%  in  the  stable  group  (p  =  0.83).  There  was
 trend  for  higher  glycaemia  at  admission  in  the  ACS
roup:  1.30  ±  0.42  g/L  vs.  1.14  ±  0.44  g/L  (p  =  0.07).  The
ean  C-reactive  protein  value  was  higher  in  the  ACS  group:
5.5  ±  3.4  mg/L  vs.  4.1  ±  3.6  mg/L  (p  =  0.05).  Total  choles-
erol  (but  not  low-density  lipoprotein  cholesterol)  was
igher  in  the  ACS  group,  as  was  triglyceridaemia.
As  shown  in  Table  3,  no  differences  were  noted  between
he  two  groups  in  terms  of  treatment  received  within  the
4  h  before  the  VerifyNow-P2Y12® test  except  for  type  of
eparin.  In  accordance  with  the  protocol,  none  of  the
atients  received  bivalirudin,  thrombolytic  and/or  glycopro-
ein  IIb/IIIa  inhibitor  treatment.  None  of  the  patients  was  on
hronic  clopidogrel  treatment  before  inclusion.
mpact of initial clinical presentation on
lopidogrel low response
s  shown  in  Fig.  2,  there  was  a  signiﬁcant  difference  in  PRU
alues  between  the  ACS  group  and  the  stable  group:  197  ±  81
s.  159  ±  94,  respectively  (p  =  0.03).  When  the  cut-off  point
f  230  was  used  to  deﬁne  patients  as  low  responders,  there
ere  19  (38%)  low  responders  in  the  ACS  group  and  9  (18%)
n  the  stable  group  (p  =  0.04).
When  PRU  was  analysed  as  a  continuous  variable,  theCS  group  was  independently  associated  with  higher  PRU
alues  by  multivariable  analysis  (p  =  0.02).  BMI  was  also  sig-
iﬁcantly  associated  with  higher  PRU  values  (p  =  0.03)  and




tion unit (PRU) values as assessed by the VerifyNow-P2Y12® test.
CS: acute coronary syndromes.
p  =  0.08)  (Table  4).  When  PRU  was  analysed  as  a  binary  vari-
ble  (low  responders  if  PRU  >  230),  the  ACS  group  was  the
nly  independent  predictor  of  low  response  to  clopidogrel
y  multivariable  analysis  (p  =  0.04).
iscussion
he  most  important  ﬁnding  in  our  prospective  study  is  that
nitial  clinical  presentation  seems  to  play  a  pivotal  role  in  the
esponse  to  clopidogrel.  Indeed,  patients  presenting  with
CS  had  signiﬁcantly  higher  platelet  reactivity  after  a  600  mg
oading  dose  of  clopidogrel  compared  with  patients  with  sta-
le  CAD  as  assessed  by  the  VerifyNow-P2Y12  test:  197  PRUs
s.  159  PRUs,  respectively.  This  difference  remained  sig-
iﬁcant  when  adjusted  for  previously  identiﬁed  modulators
f  clopidogrel  response  and  platelet  reactivity.  In  addition,
he  rate  of  low  responders  to  clopidogrel  (deﬁned  as  a  PRU
alue  >  230)  [23]  was  twofold  higher  in  the  ACS  group  com-
ared  with  in  the  stable  group.  Patients  of  both  groups  were
ell  matched.  This  suggests  that  the  evolution  of  CAD  for
ne  patient  inﬂuences  the  clopidogrel  response  over  time.
Many  studies  have  reported  the  presence  of  a  large
nterindividual  variability  in  clopidogrel  response,  especially
n  the  context  of  ACS  [1—11].  However,  the  presence  of
ny  intraindividual  variability  over  time  is  still  debated.
atients  with  low  response  to  clopidogrel  are  at  higher  risk
f  severe  cardiovascular  events,  such  as  death,  myocardial
nfarction  and/or  stent  thrombosis  [1—11]; it  may  be  critical
o  perfectly  identify  such  patients.  In  the  literature,  many
ariables  have  been  shown  to  correlate  with  low  response  to
lopidogrel.  Some  of  these  variables  are  not  modiﬁable,  such
s  genetic  polymorphism  (CYP2C19*2,  etc.)  [13—17]  and  the
resence  of  diabetes  [18].  Others,  however,  are  clearly  not
onstant  over  time,  such  as  BMI  [19]  and,  especially,  the
linical  status  of  the  patients  (ACS  or  stable  CAD).
Importantly,  some  authors  have  reported  that  there  is
articularly  high  platelet  reactivity  at  baseline  in  the  con-
ext  of  ACS  [24—27]  as  well  as  in  the  settings  of  infections
nd/or  inﬂammation.  In  1966,  Hampton  et  al.  reported  that
latelets  were  more  activated  by  ADP  and  noradrenalin  in
he  context  of  myocardial  infarction  [25]. In  addition,  some
Clinical  presentation  and  clopidogrel  resistance  597
Table  1  Baseline  clinical  characteristics  of  the  population  at  admission.
ACS  group  (n  =  50)  Stable  group  (n  =  50)  p
Age  (years)  60.9  ±  13.3  60.7  ±  11.5  0.10
Men  34  (68)  34  (68)  1
BMI  (kg/m2)  27.6  ±  5.6  27.9  ±  5.9  0.80
Diabetes  14  (28)  14  (28)  1
Tobacco  use  24  (48)  22  (44)  0.69
Hypercholesterolaemia  24  (48) 30  (60) 0.23
Hypertension  24  (48) 21  (42) 0.55
Cardiovascular  heredity 16  (32) 18  (36) 0.67
Peripheral  vascular  disease  4  (8)  2  (4)  0.40
History  of  stroke  2  (4)  3  (6)  0.65
Renal  failure  (CrCl  <  60  mL/min)  5  (10)  4  (8)  0.73
History  of  coronary  artery  disease  8  (16)  14  (7)  0.15
LVEF  (%)  54.4  ±  10.8  52  ±  13.7  0.33
Initial  presentation  as  STEMI  26  (52)  —  —
Data are mean ± standard deviation or number (%). ACS: acute coronary syndrome; BMI: body mass index; CrCl: creatinine clearance;
LVEF: left ventricular ejection fraction at admission; STEMI: ST-segment elevation myocardial infarction.
Table  2  Baseline  biological  characteristics  of  the  population  at  admission.
ACS  group  (n  =  50)  Stable  group  (n  =  50)  p
Haemoglobin  (g/L)  13.8  ±  1.7  13.9  ±  1.8  0.80
Haematocrit  (%)  40.8  ±  4.5  41.4  ±  4.7  0.46
Platelet  count  (Giga/L)  238  ±  50  231  ±  65  0.62
Creatinine  (mg/L)  10  ±  4.1  10.3  ±  5.4  0.73
C-reactive  protein  (mg/L)  15.5  ±  3.4  4.1  ±  3.6  0.05
Fibrinogen,  g/L  (±SD)  3.5  ±  1.1  3.8  ±  1.3  0.36
Total  cholesterol  (g/L)  1.91  ±  0.50  1.68  ±  0.42  0.02
LDL  cholesterol  (g/L)  1.11  ±  0.43  0.99  ±  0.36  0.13
HDL  cholesterol  (g/L)  0.46  ±  0.16  0.46  ±  0.14  0.99
Triglyceridaemia  (g/L)  1.69  ±  1.25  1.25  ±  0.66  0.03
Glycaemia  (g/L)  1.30  ±  0.42  1.14  ±  0.44  0.07
HbA1C  (%) 6.7  ±  1.5  6.8  ±  1.6  0.83
Troponin  peak  (ng/L) 51.7  ±  73.5 —  —
Data are mean ± standard deviation. ACS: acute coronary syndrome; HbA1C: glycosylated haemoglobin (diabetic patients only); HDL:
high-density lipoprotein; LDL: low-density lipoprotein.
Table  3  Treatment  within  the  24  h  before  the  VerifyNow-P2Y12® test.
ACS  group  (n  =  50)  Stable  group  (n  =  50)  p
Clopidogrel  (600  mg)  50  (100)  50  (100)  1
Intravenous  aspirin  (500  mg)  50  (100)  50  (100)  1
Unfractionated  heparin  16  (32)  50  (100)  <  0.0001
Low-molecular-weight  heparin  34  (68)  0 (0)  <  0.0001
Bivalirudin  0  (0)  0 (0)  1
Glycoprotein  IIb/IIIa  inhibitor  0  (0)  0 (0)  1
Thrombolytic  0  (0)  0 (0)  1
Statin  42  (84)  35  (70)  0.10
Proton  pump  inhibitor  17  (34)  14  (28)  0.52
Data are number (%). ACS: acute coronary syndrome.
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Table  4  Predictors  of  clopidogrel  low  response  (VerifyNow-P2Y12® test);  multivariable  analysis.
Categorical  variables








Stable  group  159  ±  94  0.03  0.02
ACS  group  197  ±  81
Age  0.28  0.004  0.08
Sex
Male  202  ±  93  0.07  0.21
Female  167  ±  86
BMI  0.22 0.03 0.03
Tobacco  use
No  155  ±  87  0.005  0.54
Yes  205  ±  86
Diabetes
No  167  ±  83  0.06  0.68
Yes  205  ±  99
Renal  failure
No  174  ±  89 0.18 0.78
Yes 216  ±  96
Statins
No  177  ±  79  0.94  0.19
Yes  179  ±  83
Proton  pump  inhibitor
No  167  ±  86  0.08  0.42
Yes  202  ±  82












































Cuthors  have  suggested  a  correlation  between  the  level
f  platelet  reactivity  at  baseline  and  the  response  to  clo-
idogrel  [24].  Gurbel  et  al.  published  data  in  accordance
ith  such  a  concept  [28].  We  subsequently  hypothesized  the
resence  of  intraindividual  variability  over  time,  related  to
he  clinical  status  of  the  patient  (ACS  versus  stable  CAD).
ur  results  seem  to  conﬁrm  the  concept  of  intraindividual
ariability  to  clopidogrel.  Indeed,  the  presence  of  ACS  was
ndependently  associated  with  a  lower  response  to  clopido-
rel.  Just  as  a  reminder,  patients  in  both  groups  were  well
atched  on  age,  sex,  diabetes  and  BMI.
Of  note,  our  results  are  also  in  accordance  with  the
esults  of  the  different  randomized  trials  assessing  the
eneﬁt  of  stronger  antiplatelet  therapies  in  the  context
f  ACS,  even  in  medically  treated  patients  (no  PCI  and
o  stent  implantation).  Patients  with  ACS  are  indeed  at
igh  risk  of  recurrent  ischaemic  events,  potentially  related
o  higher  platelet  reactivity.  In  all  these  trials,  authors
ave  subsequently  tested  stronger  antiplatelet  therapies
ithout  assessing  the  real  response  to  the  standard  dose  of
lopidogrel.  The  CURE  [29],  CREDO  [30]  and  CLARITY-TIMI
8  [31]  studies  showed  initially  that  a  standard  dose  of
lopidogrel  has  signiﬁcant  beneﬁt  on  top  of  aspirin  in
atients  with  ST-segment  elevation  or  non-ST-segment
levation  myocardial  infarction,  even  in  the  medically
reated  group.  More  recently,  the  CURRENT-OASIS  7  [32],
T
t
rLATO  [33]  and  TRITON-TIMI  38  [34]  studies  conﬁrmed  the
eed  for  higher  inhibition  of  platelet  aggregation  in  STEMI
nd  NSTEMI  patients  by  using  higher  doses  of  clopidogrel
r  more  powerful  treatments,  such  as  ticagrelor  [33]  or
rasugrel  [34,35]. By  contrast,  no  study  has  ever  shown  any
eneﬁt  for  high  doses  of  clopidogrel  or  other  more  powerful
reatment  in  stable  patients.  Together  with  our  results,
hese  observations  suggest  the  presence  of  intraindividual
ariability  in  clopidogrel  response  over  time  and  the  critical
mpact  of  ACS  in  this  setting.
If  previous  studies  have  suggested  large  interindividual
ariability  in  clopidogrel  response:  ‘‘one  size  does  not  ﬁt
ll’’;  our  study  suggests  also  the  presence  of  intraindividual
ariability:  ‘‘one  size  does  not  ﬁt  the  patient  throughout
ife’’.  The  real  problem  is  to  know  when  the  low  response
o  clopidogrel  related  to  ACS  disappears  and  when  we  could
ecrease  antiplatelet  therapies  after  ACS.  Indeed,  maintain-
ng  a  high  level  of  platelet  inhibition  when  unnecessary  could
ead  to  a high  risk  of  major  bleeding  [36].
onclusionhe  present  study  suggests  that  initial  clinical  presenta-
ion  (especially  ACS)  is  a  strong  predictor  of  clopidogrel  low
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patient  inﬂuences  clopidogrel  response  over  time.  These
results  are  in  accordance  with  recent  trials  showing  a  beneﬁt
for  increased  antiplatelet  therapy  in  ACS  patients.
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